Datopotamab deruxtecan in solid tumors: Recent research progress and clinical applications
By
Ying Cao
Li-qin Mo
Ya-juan Liu
Zhen Zhang
July 7, 2026
Clinical Scorecard: Advancements in Research and Clinical Use of Datopotamab Deruxtecan for Solid Tumors
At a Glance
Category Detail
Condition Solid Tumors Key Mechanisms TROP2-targeting antibody-drug conjugate (ADC) with a potent topoisomerase I inhibitor. Target Population Adult patients with hormone receptor-positive, HER2-negative breast cancer and EGFR-mutant non-small cell lung cancer. Care Setting Clinical oncology
Key Highlights
Datopotamab deruxtecan (Dato-DXd) shows compelling efficacy and manageable safety profile. Approved for HR+/HER2- breast cancer and EGFR-mutant NSCLC. High TROP2 expression is associated with poor prognosis in various solid tumors. Ongoing clinical trials are exploring Dato-DXd in multiple solid tumor types. Combination therapy strategies and bispecific ADCs targeting TROP2 are under investigation. Guideline-Based Recommendations
Diagnosis
Assess TROP2 expression in solid tumors to identify candidates for Dato-DXd therapy. Management
Utilize Dato-DXd for patients with HR+/HER2- breast cancer and EGFR-mutant NSCLC after prior therapies. Monitoring & Follow-up
Monitor for treatment-related adverse events and disease progression. Risks
Potential for adverse events related to the cytotoxic payload and TROP2 targeting. Patient & Prescribing Data
Adults with unresectable or metastatic solid tumors expressing TROP2.
Dato-DXd demonstrates robust antitumor activity across multiple solid tumor types.
Clinical Best Practices
Consider sequencing strategies with other TROP2-targeting ADCs. Address drug resistance mechanisms in treatment planning. Implement management strategies for treatment-related adverse events. Related Resources & Content
